tacrolimus + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Ulcerative Colitis

Conditions

Ulcerative Colitis

Trial Timeline

Sep 1, 2006 → Apr 1, 2008

NCT ID

NCT00347048

About tacrolimus + Placebo

tacrolimus + Placebo is a phase 3 stage product being developed by Astellas Pharma for Ulcerative Colitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00347048. Target conditions include Ulcerative Colitis.

What happened to similar drugs?

15 of 20 similar drugs in Ulcerative Colitis were approved

Approved (15) Terminated (5) Active (5)

✅Azathioprine + PlaceboCelltrionApproved

✅Filgotinib MaleateEisaiApproved

✅Oral Upadacitinib + Intravenous Methylprednisolone + Oral Upadacitinib Placebo + Oral prednisolone Taper + Oral Prednisone - Hospital Dose SteroidsAbbVieApproved

✅AdalimumabAbbVieApproved

✅Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg + Golimumab treatment optimization.MerckApproved

✅GolimumabMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01224028	Phase 2	Completed	Nov 1, 2010	Jun 1, 2011	IgA Nephropathy
NCT00347048	Phase 3	Completed	Sep 1, 2006	Apr 1, 2008	Ulcerative Colitis
NCT00319917	Approved	Completed	Apr 1, 2006	Oct 1, 2008	Rheumatoid Arthritis
NCT00309088	Phase 3	Completed	Apr 1, 2006	Jun 1, 2008	Myasthenia Gravis
NCT00106392	Approved	Completed	Feb 1, 2005	Nov 1, 2008	Erectile Dysfunction

Competing Products

20 competing products in Ulcerative Colitis

See all competitors

Product	Company	Stage	Hype Score
Mirikizumab SC + Mirikizumab IV + Placebo SC	Eli Lilly	Phase 3	40
Mirikizumab	Eli Lilly	Phase 2	35
Azathioprine + Placebo	Celltrion	Approved	35
CT-P13 SC (Infliximab)	Celltrion	Phase 3	40
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	44
Tacrolimus	Astellas Pharma	Phase 3	40
Filgotinib Maleate	Eisai	Approved	50
AJM300 + Placebo	Eisai	Phase 3	40
GSK3050002 + Placebo	Eisai	Phase 1	29
adalimumab + placebo	Eisai	Phase 3	40
E6007 + Placebo	Eisai	Phase 2	35
KHK4083 + Placebo	Kyowa Kirin	Phase 2	35
KHK4083 + Placebo	Kyowa Kirin	Phase 1	29
Arm1 + Arm 2	Zydus Lifesciences	Phase 2	35
Mirikizumab + Mirikizumab	Eli Lilly	Phase 3	44
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SC	Eli Lilly	Phase 3	32
LY3471851 + Placebo	Eli Lilly	Phase 2	27
Mirikizumab + Placebo	Eli Lilly	Phase 2	35
LY4268989 + Placebo	Eli Lilly	Phase 2	42
Eltrekibart + Mirikizumab + Placebo	Eli Lilly	Phase 2	42